Abstract:Abstract Background: In IMpassion031 (NCT03197935), patients (pts) (N = 333) with invasive stage II or III eTNBC who received NA treatment (tx) with atezolizumab (A) + nab-paclitaxel (nP) followed by doxorubicin + cyclophosphamide (AC; A-chemo) had significantly improved pathologic complete response (pCR, primary endpoint) regardless of PD-L1 status vs placebo (P) with nP and AC (P-chemo). Balancing efficacy and toxicity is key in this potentially curable eTNBC setting. PROs were collected to comprehensively assess tx burden from the pts’ perspective, inform clinical benefit and decision-making and address the lack of pt-reported data in this setting. Methods: Pts received double-blind A 840 mg or P every 2 weeks (q2w) with nP 125 mg/m2 once weekly for 12 wk followed by A 840 mg or P q2w with AC q2w for 4 doses. After surgery and pathological evaluation, pts in the A-chemo arm received open-label A 1200 mg every 3 weeks for 11 doses. The P-chemo arm was observed. To capture pts’ experience of tx-related symptoms, associated bother, and impact on day-to-day functioning and health-related quality of life (HRQoL), pts completed the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) and single-item GP5 from the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire at baseline (BL) and day (D)1 of each cycle (C) of NA and adjuvant (adj) tx, at end of tx and in follow-up every 3 mo (year 1), every 6 mo (years 2-3), then annually. Mean and mean change from BL scores (≥ 10-point change considered clinically meaningful) by C and between tx arms in the QLQ-C30 function (role and physical) and global health status/QoL scales were predefined secondary endpoints. Mean and mean change from BL scores in tx-related symptoms, as well as an assessment of tx side-effect bother, were exploratory endpoints. Results: QLQ-C30 completion rates (ITT) in both arms were 100% at BL and > 90% in the NA phase and > 89% in the adj phase through C16. GP5 completion rates in both arms were > 98% at BL (C2D1) and > 88% in the NA and adj phases. BL mean [95% CI] values were high for physical function (A-chemo, 91 [89-93]; P-chemo, 90 [88-92]), role function (A-chemo, 89 [86-93]; P-chemo, 89 [86-92]), and HRQoL (A-chemo, 79 [76-82]; P-chemo, 76 [73-79]). Physical and role function, and HRQoL mean values were similar between arms across on-tx assessments to C16 and through follow up. Mean change from BL values for physical and role function, and HRQoL were similar between arms and of the same magnitude. In both arms mean physical function had a clinically meaningful decline during the NA period from C3 to C5, rebounding in the adj period, and stabilizing starting C7. In both arms mean role function had a clinically meaningful decline in the NA period from C2 (A-chemo) or C3 (P-chemo) to C5, rebounding in the adj period, and stabilizing at C9 in the P-chemo arm only. In both arms mean HRQoL had a clinically meaningful decline in the NA period from C3 to C5, rebounding in the adj period and stabilizing from C6. Tx symptoms of fatigue, diarrhea, nausea, and vomiting in the NA period worsened through C5 in both arms with trends in mean and mean change from BL values similar to the functional and HRQoL data. In the adj period, mean symptom scores in both arms through C16 were similar to BL except for fatigue. 65% (A-chemo) and 66% (P-chemo) of pts reported their level of bother with tx side effects to be “somewhat” or “quite a bit” by C5. During the adj period, no added side-effect bother was experienced by pts receiving A compared with the P-chemo arm under observation, with a similar % of pts in each arm reporting being bothered “somewhat,” “quite a bit,” or “very much” by C16. Conclusions: Adding A to nP-AC improved pCR without added tx burden to pts. These results address the paucity of PRO data informing clinical benefit and decision-making in this potentially curable setting. Citation Format: Elizabeth A. Mittendorf, Nadia Harbeck, Hong Zhang, Shigehira Saji, Kyung Hae Jung, Sheetal Patel, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Stephen Y. Chui, Carlos H. Barrios. Patient-reported outcomes (PROs) from the Ph 3 IMpassion031 trial of neoadjuvant (NA) atezolizumab + chemo in early triple-negative breast cancer (eTNBC) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr GS3-02.

GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS©): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial

Capturing Patient Voice to Improve Outcomes That Matter to Patients with Desmoid Tumor

Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor.

Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study

Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study.

Abstract GS3-02: Patient-reported Outcomes (pros) from the Ph 3 IMpassion031 Trial of Neoadjuvant (NA) Atezolizumab + Chemo in Early Triple-Negative Breast Cancer (Etnbc)

Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).

Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial

Patient prioritisation of items to develop the Patient‐Reported Impact of Dermatological Diseases measure: A global Delphi study

Abstract PO1-27-10: Adjunctive statistical standardization of quantitated machine image analysis of Estrogen and Progesterone Receptors: CCTG MA.27 trial

Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)

Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis

Establishing the sensitivity and specificity of the gynaecological cancer distress screen

Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure

The effectiveness of a modified Gui Zhi Fu Ling Wan formulation (Gynoclear™) for the treatment of endometriosis: a study protocol for a placebo-controlled, double-blind, randomised controlled trial

Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India

Randomised controlled pilot trial of the EndoSMS supportive text message intervention for individuals with endometriosis: Feasibility and acceptability results

Feasibility, acceptability, and preliminary efficacy of a self-directed online psychosocial intervention for women with metastatic breast cancer: Finding My Way-Advanced

GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).